XML 42 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 3 - Summary of Significant Accounting Policies - Allocation of Consideration Transferred (Details) - Protagenic Therapeutics Inc [Member]
Feb. 12, 2016
USD ($)
Total value of shares issued to Atrinsic on Merger $ 404,169
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net 0
Goodwill 404,169
Common Stock [Member]  
Atrinsic 32,334
Preferred Stock [Member] | Series B Preferred Stock [Member]  
Atrinsic $ 371,835